drugset / Trial / NCT03882983

Stromal Vascular Fraction From Lipoaspirate to Treatment of Chronic Non-healing Wound

NCT03882983

Phase 1 Unknown 40 enrolled Antria
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I, open-label, single arm study to demonstrate the safety of Antria Cell Preparation Process during fat grafting augmented with autologous adipose derived stromal vascular fraction to demonstrate the safety and efficacy of administration of SVF enriched fat grafting in chronic wounds

Timeline

Start
2017-09-01
Primary completion
2022-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rexlemestrocel-L Cell therapy

Indications